secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001516551-23-000004
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience extends credit agreement maturity to Feb 28, 2023 or sale of Verdélite Sciences
--------------------------------------------------------------------------------

- Amendment No. 5 to Multi Draw Credit Agreement with Emerald Health Sciences extends maturity to earlier of sale of Verdélite Sciences, Feb 28, 2023, or termination date.
- Director Bobby Rai appointed to Nominating and Corporate Governance Committee on January 5, 2023.
- Credit agreement originally dated April 1, 2020, previously amended in March, September, and November 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000004/0001516551-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000004/skye-20221230.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer